The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: Current situation and recommendations;Utilisation de la corticothérapie postnatale chez le nouveau-né prématuré dans la prévention et le traitement de la dysplasie bronchopulmonaire état des lieux et conduite à tenir

Archives de Pediatrie

Volumn 17, Issue 10, 2010, Pages 1480-1487

  Jarreau, P H ^a   Fayon, M ^b   Baud, O ^c   Autret Leca, E ^d   Danan, M ^e   de Verdelhan, A ^e   Castot, A ^e  

^a Institut Cochin   (France)

^b HÔPITAL PELLEGRIN   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d CHU BRETONNEAU   (France)

^e AFSSAPS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG INDICATION; DRUG UTILIZATION; EARLY INTERVENTION; EXTUBATION; FRANCE; HEALTH CARE FACILITY; HUMAN; LUNG DYSPLASIA; MEDICAL DECISION MAKING; NEUROLOGIC DISEASE; NOSE BREATHING; OXYGEN THERAPY; PATIENT SAFETY; POSTNATAL CARE; PRACTICE GUIDELINE; PREMATURITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 78650075291     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2010.07.013     Document Type: Article

References (36)

1. Fauroux B. Dysplasie bronchopulmonaire. 2005 ; http://www.sfip-radiopediatrie.org/.
2. Northway W.H., Rosan R.C., Porter D.Y. Pulmonary disease following respirator therapy of hyaline-membrane disease, bronchopulmonary dysplasia. N Engl J Med 1967, 276:357-368.
3. Mammel M.C., Green T.P., Johnson D.E., et al. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983, 1:1356-1358.
4. Cummings J.J., D'Eugenio D.B., Gross S.J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989, 320:1505-1510.
5. Noble-Jamieson C.M., Regev R., Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. Eur J Pediatr 1989, 148:365-367.
6. Jobe A.H. The new bpd: an arrest of lung development. Pediatr Res 1999, 46:641-643.
7. Jobe A.H., Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998, 53:81-94.
8. Halliday H.L., Ehrenkranz R.A. Early postnatal (<96hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003, 1. [CD001146].
9. Halliday H.L., Ehrenkranz R.A. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003, 1. [CD001144].
10. Halliday H.L., Ehrenkranz R.A. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003, 1. [CD001145].
11. Halliday H.L. Early postnatal dexamethasone and cerebral palsy. Pediatrics 2002, 109:1168-1169.
12. Yeh T.F., Lin Y.J., Lin H.C., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004, 350:1304-1313.
13. Murphy B.P., Inder T.E., Huppi P.S., et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001, 107:217-221.
14. Doyle L.W., Davis P.G., Morley C.J., et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006, 117:75-83.
15. O'Shea T.M., Washburn L.K., Nixon P.A., et al. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics 2007, 120:594-602.
16. Karna P., Muttineni J., Angell L., et al. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr 2005, 28(5):18.
17. Smolkin T., Steinberg M., Sujov P., et al. Late postnatal systemic steroids predispose to retinopathy of prematurity in very-low-birth-weight infants: a comparative study. Acta Paediatr 2008, 97:322-326.
18. Lin Y.J., Lin C.H., Wu J.M., et al. The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatr 2005, 94:310-316.
19. Nixon P.A., Washburn L.K., Schechter M.S., et al. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. J Pediatr 2007, 150:345-350.
20. Bourbon J., Boucherat O., Chailley-Heu B., et al. Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. Pediatr Res 2005, 57:38R-46R.
21. Bland R.D., Coalson J.J. Chronic lung disease in early infancy 2000, 1062. Marcel Dekker, New York.
22. McDonald J.A. Lung growth and development 1997, 740. Marcel Dekker, New York.
23. Massaro D., Massaro G.D. Retinoids, alveolus formation, and alveolar deficiency: clinical implications. Am J Respir Cell Mol Biol 2003, 28:271-274.
24. Fanucchi M.V., Plopper C.G. Environmental toxicants and lung development in experimental models. The lung. Development, aging, and the environment 2004, 345-351. Elsevier, London. R. Harding, K.E. Pinkerton, C.G. Plopper (Eds.).
25. Fayon M., Jouvencel P., Carles D., et al. Differential effect of dexamethasone and hydrocortisone on alveolar growth in rat pups. Pediatr Pulmonol 2002, 33:443-448.
26. Tschanz S.A., Makanya A.N., Haenni B., et al. Effects of neonatal high-dose short-term glucocorticoid treatment on the lung: a morphologic and morphometric study in the rat. Pediatr Res 2003, 53:72-80.
27. Baud O., Fiox-L'Helias L., Kaminski M., et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999, 341:1190-1196.
28. Decastro M., El-Khoury N., Parton L., et al. Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study. J Perinatol 2009, 29:297-304. [Epub ahead of print].
29. Cambonie G., Mesnage R., Milési C., et al. Betamethasone impairs cerebral blood flow velocities in very premature infants with severe chronic lung disease. J Pediatr 2008, 152:270-275.
30. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004, 114:1649-1657.
31. Watterberg K.L., Shaffer M.L., Mishefske M.J., et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007, 120:40-48.
32. Bhandari A., Schramm C.M., Kimble C., et al. Effect of a short course of prednisolone in infants with oxygen-dependent bronchopulmonary dysplasia. Pediatrics 2008, 121:e344-e349.
33. Sorkness R.L., Remus J.L., Rosenthal L.A. Systemic and pulmonary effects of fluticasone administered through a metered-dose inhaler in rats. J Allergy Clin Immunol 2004, 114:1027-1032.
34. Kovar J., Willet K.E., Hislop A., et al. Impact of postnatal glucocorticoids on early lung development. J Appl Physiol 2005, 98:881-888.
35. Autret-Leca E., Bauer S., Alberti C., et al. Corticothérapie postnatale chez le prématuré étude des pratiques des centres français de néonatalogie en 2006. Arch Pediatr 2009, 16:999-1004.
36. Committee on fetus and newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002, 109:330-338. American Academy of Pediatrics.